RLAY

3.60

2.27% 0.08

Dopo l'orario di chiusura: 3.60

Relay Therapeutics Inc (RLAY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RLAY Giù? Forum Previsione

Precedente Chiudi:

$3.52

Aprire:

$3.53

Volume 24 ore:

1.54M

Relative Volume:

0.67

Capitalizzazione di mercato:

$598.34M

Reddito:

$25.55M

Utile/perdita netta:

$-341.97M

Rapporto P/E:

-1.2857

EPS:

-2.8

Flusso di cassa netto:

$-304.44M

1 W Prestazione:

+10.43%

1M Prestazione:

+13.21%

6M Prestazione:

-16.28%

1 anno Prestazione:

-44.36%

Intervallo 1D:

$3.49

$3.75

Intervallo di 1 settimana:

$3.20

$3.75

Portata 52W:

$1.775

$10.72

Relay Therapeutics Inc Stock (RLAY) Company Profile

Nome

Relay Therapeutics Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

617-370-8837

Indirizzo

399 BINNEY STREET, CAMBRIDGE

Dipendente

259

Cinguettio

Prossima data di guadagno

2025-02-21

Ultimi documenti SEC

RLAY's Discussions on Twitter

Confronta RLAY con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RLAY Relay Therapeutics Inc	3.60	598.34M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-17	Iniziato	Wells Fargo	Equal Weight
2024-09-10	Ripresa	Goldman	Buy
2024-09-10	Aggiornamento	Jefferies	Hold → Buy
2024-09-10	Downgrade	Oppenheimer	Outperform → Perform
2024-05-10	Aggiornamento	Barclays	Equal Weight → Overweight
2023-04-20	Aggiornamento	Jefferies	Underperform → Hold
2023-04-19	Aggiornamento	Raymond James	Outperform → Strong Buy
2023-04-13	Iniziato	Raymond James	Outperform
2023-02-03	Iniziato	Oppenheimer	Outperform
2022-09-30	Iniziato	Barclays	Equal Weight
2022-09-02	Iniziato	Stifel	Buy
2022-06-06	Iniziato	Jefferies	Underperform
2022-02-01	Iniziato	Berenberg	Buy
2021-07-21	Iniziato	BofA Securities	Buy
2020-12-15	Reiterato	H.C. Wainwright	Buy
2020-12-08	Iniziato	JMP Securities	Mkt Outperform
2020-11-05	Iniziato	H.C. Wainwright	Buy
2020-08-10	Iniziato	Cowen	Outperform
2020-08-10	Iniziato	Goldman	Buy
2020-08-10	Iniziato	Guggenheim	Buy
2020-08-10	Iniziato	JP Morgan	Neutral

Mostra tutto

Relay Therapeutics Inc Borsa (RLAY) Ultime notizie

Jun 18, 2025

In the Green: Relay Therapeutics Inc (RLAY) Closes at 3.06, Up/Down -6.42 from Previous Day - DWinneX

Jun 18, 2025

Jun 14, 2025

Relay Therapeutics’ SWOT analysis: AI-driven drug discovery stock faces pivotal phase - Investing.com India

Jun 14, 2025

Jun 12, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by California State Teachers Retirement System - Defense World

Jun 12, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus

Jun 12, 2025

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar to Board of Directors - citybiz

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com India

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial By Investing.com - Investing.com South Africa

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - MarketScreener

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Bluefield Daily Telegraph

Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,293 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 11, 2025

Jun 10, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025

Jun 09, 2025